| Multiple Myeloma
Aphexda vs Tecvayli
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Aphexda vs Tecvayli with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecvayli has a higher rate of injection site reactions vs Aphexda based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecvayli but not Aphexda, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aphexda
Tecvayli
At A Glance
SC injection
Per apheresis (up to 2 doses)
CXCR4 inhibitor
SC injection
Weekly to every 4 weeks
BCMA-directed CD3 T-cell engager
Indications
- Multiple Myeloma
- Multiple Myeloma
Dosing
Multiple Myeloma 1.25 mg/kg via slow SC injection 10 to 14 hours before first apheresis, following 4 days of filgrastim pretreatment; premedicate with diphenhydramine, an H2 blocker, and a leukotriene inhibitor 30 to 60 minutes before each dose; a second dose may be given 10 to 14 hours before a third apheresis if necessary.
Multiple Myeloma (combination with daratumumab and hyaluronidase-fihj) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 3), then 1.5 mg/kg once weekly (weeks 2-8), 3 mg/kg every 2 weeks (weeks 9-24), and 3 mg/kg every 4 weeks (week 25 onward); administer until disease progression or unacceptable toxicity.
Multiple Myeloma (monotherapy) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 4), then 1.5 mg/kg once weekly; may reduce to 1.5 mg/kg every 2 weeks for patients with complete response or better maintained for at least 6 months.
Contraindications
- History of serious hypersensitivity reactions to motixafortide
—
Adverse Reactions
Most common (>20%) Injection site reactions (pain, erythema, pruritus), pruritus, flushing, back pain
Serious Vomiting, injection site reaction, hypersensitivity reaction, injection site cellulitis, hypokalemia, hypoxia
Most common (>=20%) pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, diarrhea, hypogammaglobulinemia, cough, COVID-19, gastroenteritis, weight decreased
Serious pneumonia, cytokine release syndrome, sepsis, pyrexia, COVID-19, febrile neutropenia, gastroenteritis, acute kidney injury, encephalopathy, second primary malignancy
Pharmacology
Motixafortide is a CXCR4 inhibitor that blocks binding of SDF-1alpha/CXCL12 to CXCR4, disrupting stem cell anchoring in the bone marrow and mobilizing hematopoietic stem and progenitor cells into the peripheral circulation.
Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds CD3 on T-cells and BCMA on multiple myeloma cells, activating T-cells to release proinflammatory cytokines and lyse myeloma cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aphexda
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Tecvayli
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Aphexda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tecvayli
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Aphexda
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Tecvayli
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
BioLineRx Connect Patient Assistance Program: AphexdaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
J&J withMe Savings Program: TecvayliCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AphexdaView full Aphexda profile
TecvayliView full Tecvayli profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.